Bio Pharma Dive
NOVEMBER 15, 2022
Acrivon is the 20th biotech company to go public this year, roughly a fifth of last year’s total at this time, and had to sell more shares at a lower price to complete the deal.
AuroBlog - Aurous Healthcare Clinical Trials blog
NOVEMBER 15, 2022
Scientists from the Dana-Farber Cancer Institute have found some male cancer cells, those with X and Y chromosomes, show signs of having their X chromosome silenced. In normal mammal cells, the X chromosome is only muted when a female cell has a pair of Xs to choose from. Randomly turning off an extra X is […].
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
NOVEMBER 15, 2022
Backed by the same investors and team as an immunotherapy biotech Roche bought in September, Bonum Therapeutics plans to develop “conditionally” active cancer medicines.
Pharmaceutical Technology
NOVEMBER 15, 2022
Indivior has signed a definitive agreement to acquire all outstanding shares of Opiant Pharmaceuticals for an upfront payment of $20 for each share in cash or a deal totalling nearly $145m. In addition to the upfront consideration, Opiant is entitled to get up to $8 for a share in contingent value rights (CVRs). . This amount is payable on meeting specific net revenue milestones during the applicable seven-year period following the approval and launch of Opiant’s lead asset, OPNT003.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Bio Pharma Dive
NOVEMBER 15, 2022
Only a small fraction of the companies Lilly evaluates get into its incubator, according to Gilmore. Here’s how the big pharma selects them.
Pharmaceutical Technology
NOVEMBER 15, 2022
Jnana Therapeutics and Roche have signed a second partnership and licence agreement to discover small-molecule drugs to treat cancer, immune-mediated and neurological ailments. The deal covers multiple targets from a varying range of target classes for addressing ailments with high unmet needs. For discovering new small molecule drugs against various disease targets, Jnana will leverage its RAPID chemoproteomics platform.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharmaceutical Technology
NOVEMBER 15, 2022
When it comes to vaccines and other high-value biologics, it is essential that effective formulations go hand in hand with safe delivery. Manufacturers are actively looking at ways they can improve drug delivery through well-designed parenteral packaging systems, and the choice to deploy prefilled syringes for more and more injectable drug products is a key part of this push.
Bio Pharma Dive
NOVEMBER 15, 2022
The company secured $157 million between its second partnership agreement with Roche and a Series C round.
Pharmaceutical Technology
NOVEMBER 15, 2022
Exscientia and The University of Texas MD Anderson Cancer Center in the US have entered a strategic partnership to use artificial intelligence (AI) to develop new cancer therapies. Under the collaboration, the parties will align Exscientia’s patient-centric AI expertise with MD Anderson’s drug discovery and development capabilities to progress new small-molecule treatments in oncology.
AuroBlog - Aurous Healthcare Clinical Trials blog
NOVEMBER 15, 2022
The Union ministry of health and family welfare (MoHFW) has notified inclusion of Coronary Stents in the National List of Essential Medicines (NLEM), 2022, with immediate effect based on the recommendations by the expert committee constituted to review and revise the list based on requirement. The Standing National Committee on Medicines (SNCM), on November 6 […].
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
NPR Health - Shots
NOVEMBER 15, 2022
State law at the time prohibited abortion after around 6 weeks. Legal experts say this kind of law leaves doctors uncertain of what's legal and can put patients in dangerous situations.
STAT News
NOVEMBER 15, 2022
As the Covid-19 pandemic spread across the world two years ago, one of India’s leading biotech companies was racing to develop a vaccine with crucial backing from the Indian government. The shot engineered by Bharat Biotech was, in part, an important effort to create a home-grown product that could bolster the fortunes of the Indian pharmaceutical industry.
Bio Pharma Dive
NOVEMBER 15, 2022
The digital therapeutics company said the reductions will extend its cash runway and curb its reliance on financing.
pharmaphorum
NOVEMBER 15, 2022
A new survey conducted by juli, an AI-powered chronic condition platform, has revealed that the value placed on digital privacy differs widely among US users. With the HLTH 2022 event now well underway, digital health industry leaders all gathered together to attend in Las Vegas this week, the juli survey results reveal consumer responses to be more varied than one would have expected when it comes to data privacy.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
STAT News
NOVEMBER 15, 2022
BOSTON — The executives behind Altos Labs would really, really like people to stop saying they’re trying to reverse aging. They have a couple things going against them on this count. For one, the first article about the biotech and its $3 billion stash talked about Silicon Valley billionaires “ living forever.” And then there’s their most prominent scientist’s tendency to talk openly about people living to 130.
Medical Xpress
NOVEMBER 15, 2022
The business magnate and new owner of Twitter Elon Musk revealed a while ago that he is autistic. Musk, the wealthiest person in the world, is autistic. Musk, a fellow of the prestigious Royal Society and Time's 2021 Person of the Year, is autistic. One of the most famous people on Earth is autistic. Perhaps it is worth letting that sink in?
STAT News
NOVEMBER 15, 2022
True to its e-commerce expertise, Amazon is jumping into the world of direct-to-consumer telehealth. On Tuesday, the tech goliath launched a virtual health storefront that individuals can access through the main Amazon website and its mobile app, offering the ability to message teleproviders and obtain prescriptions for about 20 health conditions. Amazon has been making significant shifts in its health care strategy in the last few months: In July, it announced plans to acquire primary care comp
pharmaphorum
NOVEMBER 15, 2022
Early on Day 2, Matthew Holt (who we recently featured in our Health Innovators video series ) will interview Walmart EVP Dr. Cheryl Pegus & SCAN Health Plan’s Dr. Sachin Jain. Then we’ll hear from Aptar Digital Health’s Sai Shankar and Pierre Laurent in a session all about patients as partners in healthcare. The day will continue with other hot topics for pharma, including health equity, cell and gene therapy, oncology, and pharmacy model disruption.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
STAT News
NOVEMBER 15, 2022
Medicare Advantage began life as a brilliant idea: a public-private partnership to keep older people healthier and reduce costs. At the time in 1992, both President George H.W. Bush and his challenger, Bill Clinton, supported it. An editorial in The New York Times declared, “The debate over health care reform is over. Managed competition has won.
NPR Health - Shots
NOVEMBER 15, 2022
The retail giant become the latest major player in the drug industry to announce a plan to settle lawsuits filed by state and local governments over the toll of opioids sold at its pharmacies. (Image credit: Nam Y.
BioSpace
NOVEMBER 15, 2022
In the acquisition, announced Wednesday, Kriya picks up two gene therapy programs focused on epilepsy and trigeminal neuralgia. Financial terms of the deal were not disclosed.
Medical Xpress
NOVEMBER 15, 2022
More than 1 billion teens and young people are potentially at risk of hearing loss because of their use of headphones and earbuds and attendance at loud music venues, concludes a pooled data analysis of the available evidence, published in the open access journal BMJ Global Health.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
pharmaphorum
NOVEMBER 15, 2022
Swiss pharma group Roche has doubled down on a partnership with Jnana Therapeutics, paying $50 million upfront to tap into the Boston-based biotech drug discovery platform for a wide-ranging push across cancer, immune-mediated, and neurological diseases. The new agreement – announced on the same day that Jnana finalised a $107 million series C financing – has a potential deal value of around $2 billion and comes two years after Roche paid $40 million upfront with $1 billion at the back-end for a
Medical Xpress
NOVEMBER 15, 2022
New research from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King's College London has found no evidence that cannabidiol (CBD) reduces the negative effects of cannabis.
pharmaphorum
NOVEMBER 15, 2022
Two and a half years ago, Covid-19 began to infect hundreds, then thousands, then millions of people, and was eventually declared a global pandemic. Lockdowns and 25-second handwashing, face masks, home-schooling, and working from home became the new normal. The term “social distancing” entered into common parlance and we transitioned to a life largely spent at home.
NPR Health - Shots
NOVEMBER 15, 2022
March of Dimes' annual report on infant and maternal health drops the U.S. from a C- to a D+, citing a 15-year high in the preterm birth rate. But it also offers some encouraging signs and solutions.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
BioPharma Reporter
NOVEMBER 15, 2022
Roche announced yesterday that Phase 3 studies for its Alzheimerâs drug gantenerumab failed to meet the primary endpoint of slowing clinical decline. Although disappointed, Alzheimerâs associations are hopeful there is still a lot that can be learned from the data.
Medical Xpress
NOVEMBER 15, 2022
E-cigarettes and marijuana have harmful effects on the heart similar to those caused by tobacco cigarettes, opening the door to abnormal heart rhythms, reports a team of researchers at UC San Francisco.
STAT News
NOVEMBER 15, 2022
BOSTON — In science journalism, there’s a well-worn technique reporters reach for when they’re interviewing a researcher and the technical material starts whizzing over their heads. “OK, explain it again, and this time, as if you were talking to your mother.” The conjured image of a parent tends to do just the trick; prompting an illuminating alchemy of clarity infused with excitement.
Medical Xpress
NOVEMBER 15, 2022
Growing research indicates that one's purpose—i.e., the extent to which someone perceives a sense of direction and goals in their life—may be linked to health-protective benefits such as better physical functioning and lower risks of cardiovascular disease or cognitive decline.
Advertisement
The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. Demand-led supply and direct-to-patient distribution are next-generation solutions that are helping to meet these growing needs, allowing for more streamlined processes and patient-centric studies.
Expert insights. Personalized for you.
334 
Let's personalize your content